There are no official guidelines to assist in answering this question. I will search for relevant research papers instead.
The FDA Drug Labels for immunoglobulin (IV) do not address this question.
From the Research
Role of Intravenous Immunoglobulin (IVIG) with Hemodialysis
- IVIG is a mainstay of therapy in many disorders, but it can cause acute renal failure, which may require hemodialysis 1, 2, 3.
- The risk factors for IVIG-related acute renal failure include pretreatment renal impairment, diabetes mellitus, high concentration of sucrose or glucose in IVIG preparation, and older age 2.
- IVIG-related hemolysis is another uncommon adverse side effect, which can be linked to anti-A and anti-B hemagglutinins in the IVIG preparations 4.
- Studies have shown that IVIG can be safely administered to patients on hemodialysis, with no increased risk of adverse events 5.
- However, different IVIG products may have varying adverse event profiles, and the choice of product should be based on the individual patient's needs and risk factors 5.
Adverse Events Associated with IVIG
- Acute renal failure is a known but rare adverse reaction to IVIG therapy, which can be reversible after withdrawal of the drug 1, 2, 3.
- Other adverse events associated with IVIG include hemolysis, acute myocardial infarction, and infusion-related reactions 4, 5.
- The safety and efficacy of IVIG products can vary depending on the excipients and concentration of the product 5.
Hemodialysis in IVIG-Related Acute Renal Failure
- Hemodialysis may be required in patients who develop acute renal failure after IVIG therapy 1, 2, 3.
- The use of hemodialysis in these patients can help to reverse the renal failure and improve outcomes 1, 2, 3.
- IVIG can be safely administered to patients on hemodialysis, with careful monitoring of renal function and adjustment of the dose as needed 5.